JP2024525566A - Ｐｄ‐１抗体の医薬組成物及びその使用 - Google Patents

Ｐｄ‐１抗体の医薬組成物及びその使用 Download PDF

Info

Publication number
JP2024525566A
JP2024525566A JP2024500249A JP2024500249A JP2024525566A JP 2024525566 A JP2024525566 A JP 2024525566A JP 2024500249 A JP2024500249 A JP 2024500249A JP 2024500249 A JP2024500249 A JP 2024500249A JP 2024525566 A JP2024525566 A JP 2024525566A
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
retifanlimab
composition
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525566A5 (https=
JPWO2023283049A5 (https=
Inventor
サンパスクマール，クリシュナン
チョウ，ヤン
バーク，スティーブン，ジェームズ
Original Assignee
マクロジェニクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マクロジェニクス，インコーポレーテッド filed Critical マクロジェニクス，インコーポレーテッド
Publication of JP2024525566A publication Critical patent/JP2024525566A/ja
Publication of JP2024525566A5 publication Critical patent/JP2024525566A5/ja
Publication of JPWO2023283049A5 publication Critical patent/JPWO2023283049A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2024500249A 2021-07-09 2022-06-22 Ｐｄ‐１抗体の医薬組成物及びその使用 Pending JP2024525566A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163220006P 2021-07-09 2021-07-09
US63/220,006 2021-07-09
PCT/US2022/034493 WO2023283049A1 (en) 2021-07-09 2022-06-22 Pharmaceutical compositions of a pd-1 antibody and use of the same

Publications (3)

Publication Number Publication Date
JP2024525566A true JP2024525566A (ja) 2024-07-12
JP2024525566A5 JP2024525566A5 (https=) 2025-06-30
JPWO2023283049A5 JPWO2023283049A5 (https=) 2025-06-30

Family

ID=82608118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500249A Pending JP2024525566A (ja) 2021-07-09 2022-06-22 Ｐｄ‐１抗体の医薬組成物及びその使用

Country Status (17)

Country Link
US (2) US12364756B2 (https=)
EP (1) EP4366692A1 (https=)
JP (1) JP2024525566A (https=)
KR (1) KR20240035533A (https=)
CN (1) CN118215465A (https=)
AR (1) AR126404A1 (https=)
AU (1) AU2022307332A1 (https=)
CA (1) CA3224640A1 (https=)
CL (1) CL2024000077A1 (https=)
CO (1) CO2024000198A2 (https=)
CR (1) CR20240065A (https=)
EC (1) ECSP24008791A (https=)
IL (1) IL309985A (https=)
MX (1) MX2024000268A (https=)
PE (1) PE20240797A1 (https=)
TW (1) TW202308694A (https=)
WO (1) WO2023283049A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1946776T (pt) * 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
WO2017019846A1 (en) * 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US12150990B2 (en) * 2017-11-02 2024-11-26 Nanjing Shunxin Pharmaceutical Co., Ltd. Pharmaceutical composition of humanized monoclonal anti-PD-L1 antibody
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
CN110404066B (zh) * 2018-04-28 2022-06-17 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
EP4007602A1 (en) * 2019-08-01 2022-06-08 Incyte Corporation A dosing regimen for an ido inhibitor
PH12022550244A1 (en) * 2019-08-05 2022-12-12 Nat Cancer Ct Biomarkers for determining the efficacy of immune checkpoint inhibitors

Also Published As

Publication number Publication date
WO2023283049A1 (en) 2023-01-12
TW202308694A (zh) 2023-03-01
CA3224640A1 (en) 2023-01-12
MX2024000268A (es) 2024-01-31
KR20240035533A (ko) 2024-03-15
CN118215465A (zh) 2024-06-18
AU2022307332A1 (en) 2024-01-18
ECSP24008791A (es) 2024-03-01
US20230025464A1 (en) 2023-01-26
CL2024000077A1 (es) 2024-08-23
EP4366692A1 (en) 2024-05-15
CO2024000198A2 (es) 2024-02-05
IL309985A (en) 2024-03-01
US12364756B2 (en) 2025-07-22
AR126404A1 (es) 2023-10-11
CR20240065A (es) 2024-04-08
PE20240797A1 (es) 2024-04-18
US20250345422A1 (en) 2025-11-13

Similar Documents

Publication Publication Date Title
JP6759276B2 (ja) 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
JP6396565B2 (ja) 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
JP2022066345A (ja) 安定な抗ｉｆｎａｒ１製剤
AU2013334740A1 (en) Stable, low viscosity antibody formulation
TW201641104A (zh) Ｉｌ－１７抗體之醫藥產品及穩定之液體組合物
TWI609696B (zh) 包含抗－ｄｌｌ４抗體的穩定化調配物
US12364756B2 (en) Pharmaceutical compositions of a PD-1 antibody and use of the same
EA050933B1 (ru) Фармацевтические композиции антитела к pd-1 и применение указанной композиции
HK40112469A (zh) Pd-1抗体的药物组合物及其用途
KR20240100493A (ko) 항-cd22 항체의 수성 제제 및 이의 용도
US11459399B2 (en) Pharmaceutical compositions of a HER2/neu antibody and use of the same
JP2024526773A (ja) Ｂ７‐ｈ３抗体の医薬組成物及びその使用
WO2022120014A1 (en) Pharmaceutical compositions of a her2/neu antibody and use of the same
US20230053747A1 (en) Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same
JP7851889B2 (ja) Ｉｌ－１７抗体の医薬製品および安定した液体組成物
CN116916952A (zh) HER2/neu抗体的药物组合物及其用途
HK40102521A (zh) Her2/neu抗体的药物组合物及其用途
HK40115478A (zh) 抗cd22抗体的水性制剂及其用途
WO2025140467A1 (zh) 稳定的高浓度抗pd-1抗体药物制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250620